Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 31%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a global biotechnology company with a strong portfolio of therapies for infectious diseases such as HIV and hepatitis B and C. The recent acquisition of Pharmasset has brought a potential blockbuster drug for hepatitis C, enhancing Gilead's position in the market. In the near term, the company's success will depend on the adoption and growth of its HIV therapies, while longer term, its pipeline in cell therapy and oncology could drive further growth. The company is also focused on sustainability and diversity, which could help enhance its reputation and attract talent.

Bears say

Gilead Sciences is facing potential surprise competition for its HIV PrEP franchise with the FDA acceptance of 300 mg QW oral Yeztugo. Additionally, its pipeline may face challenges from emerging oral competitors and clinical trial risks. Furthermore, Gilead may be impacted by macroeconomic factors due to COVID-19. Despite having strong leadership in the HIV market, the company may experience pricing pressure in the future, and its oncology assets may face commercial and scientific complexities. Gilead's commitment to transparency and strong governance practices may provide some reassurance, but it remains to be seen how the company will navigate these challenges and maintain positive cash flows.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 31% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $156.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $156.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.